Selection bias is not a good reason for advising more than 5 years of adjuvant hormonal therapy for all patients with locally advanced prostate cancer treated with radiotherapy

J Clin Oncol. 2009 Nov 20;27(33):e201-2; author reply e204. doi: 10.1200/JCO.2009.23.3601. Epub 2009 Sep 28.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use*
  • Combined Modality Therapy
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Invasiveness / pathology*
  • Neoplasm Staging
  • Prostatic Neoplasms / mortality*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Radiotherapy Dosage
  • Radiotherapy, Adjuvant
  • Selection Bias*
  • Survival Analysis
  • Time Factors
  • Treatment Outcome

Substances

  • Androgen Antagonists